Summary & Overview
HCPCS J1305: Evinacumab-dgnb Injection, 5 mg
HCPCS Level II code J1305 denotes injection of evinacumab-dgnb in 5 mg units, an injectable biologic therapy used in specialty lipid management and related indications. Nationally, accurate coding for high-cost biologic agents like evinacumab is critical for claims adjudication, benefit design, and utilization oversight. This code establishes unit-based billing for the drug component separate from administration services.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role and billing context, payer coverage focus, and practical considerations for service setting and unitization. The publication outlines benchmarks for unit reporting, common modifiers associated with drug billing, and policy updates affecting reimbursement and prior authorization practices.
The article provides clinicians, billing staff, and policy analysts with clear information about what J1305 represents, where the service is typically delivered, and which major payers are relevant to coverage discussions. It also identifies where input data are absent and directs readers to review payer-specific medical and pharmacy policies for detailed coverage criteria and fee schedules.
Billing Code Overview
HCPCS Level II code J1305 represents an injection formulation of evinacumab-dgnb, with each billing unit covering 5 mg of the drug. The service type is injectable medication administration, typically delivered in outpatient infusion centers, specialty clinics, or hospital outpatient departments depending on clinical need and payer policies.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with homozygous familial hypercholesterolemia (HoFH) or severe refractory hypercholesterolemia attends a specialty infusion clinic for administration of a monoclonal antibody therapy, J1305 (evinacumab-dgnb, 5 mg). The typical patient is an adult or adolescent referred by a cardiologist, lipid specialist, or endocrinologist after inadequate response to maximally tolerated lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) and when LDL-C remains markedly elevated. Prior to the visit, baseline labs including lipid panel, liver function tests, and pregnancy testing (if applicable) are reviewed. The patient is screened for active infections and infusion contraindications.
On arrival, nursing performs an intake assessment, documents vitals and allergy history, and obtains informed consent for infusion. An intravenous catheter or appropriate peripheral access is prepared if the product is administered IV (based on product instructions). The infusion or injection is prepared by pharmacy per institutional protocol and administered by an RN or qualified infusion nurse. The patient is observed during and after the injection for immediate reactions; emergency medications and resuscitation equipment are available. Post-administration documentation includes lot number, NDC/HCPCS J1305 units administered, site of administration, and any patient response or adverse events.
Typical site of service: outpatient infusion clinic, specialty ambulatory infusion center, or hospital outpatient department. Service type: specialty drug injection/infusion therapy for lipid-lowering management in patients with severe familial or refractory hypercholesterolemia.
Coding Specifications
| Modifier | Description |
|---|